David Protein-CEO: GLP-1-medicijnen maken dieettrends overbodig

The rise of GLP-1 weight-loss medications is reshaping the food industry, according to David Protein CEO Peter Rahal, who argues that traditional diet fads like keto and paleo are losing relevance. Rahal, who previously sold RXBar to Kellogg's for $600 million, suggests the unpredictable nature of these drugs makes forecasting future food trends increasingly difficult.